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lTATE-OF-THE-ART-PAPER1553The Role of Endothelial Progenitor Cells After PCIareth J. Padfield, David E. Newby, Nicholas L. Mills
ercutaneous coronary intervention (PCI) produces mechanical endovascular injury and
ndothelial denudation. In this review, Padfield and colleagues suggest that circulating
ndothelial progenitor cells (EPCs) are essential for restoring normal vascular homeostasis and
egulation of neointimal hyperplasia. EPCs are mobilized following vascular injury, home to
ites of vascular injury, and secrete angiogenic factors which encourage endothelial cell
roliferation and migration. The potential to augment this response with pharmacological,
ellular, and stent-based therapies are also reviewed.VIEWPOINT IEWPOINT1566Extracardiac Findings on Cardiac CT: A Radiologist’s Perspectiveevin M. Johnson
here has been debate in the cardiology literature as to how to handle unexpected noncardiac
ndings on cardiac computed tomography (CT) examinations. Johnson offers his perspective
s a radiologist that all structures on the images should be assessed and that the reader needs
o identify potentially important findings and recommend appropriate interventions or follow-
p. Cardiologists who take primary responsibility for cardiac CT examinations must have a
nowledge of common trivial findings, normal variants, and the customary work-up and
ollow-up recommendations.VIEWPOINT AND COMMENTARY IEWPOINT AND COMMENTARYDronedarone for Atrial Fibrillation1569avid Singh, Eugenio Cingolani, George A. Diamond, Sanjay Kaul
1577hristian Torp-Pedersen, Ole Dyg Pedersen, Lars Køber
ronedarone was recently approved for the prevention of cardiovascular hospitalization driven
y atrial fibrillation/flutter. Singh and colleagues review the evidence and conclude that
ronedarone has limited efficacy and enough questions about its safety to relegate to a
econd- or third-line agent. Torp-Pedersen and colleagues offer their view of the evidence for
ronedarone and other antiarrhythmic medications. Their conclusion is that for patients
ithout a history of congestive heart failure, dronedarone is the only antiarrhythmic drug with
arge enough clinical trial experience to prove reasonable safety.(continued on page A-20)
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ELINICAL TRIALS1580DES May Prevent Amputations in Patients With BTK Ischemiandrew J. Feiring, Mari Krahn, Lori Nelson, Amy Wesolowski, Daniel Eastwood, Aniko Szabo
atients with critical limb ischemia (CLI) have a 1-year amputation rate of 30% and
ortality rate of 25%; both balloon angioplasty and bare-metal stenting are limited by high
ates of restenosis, especially for below-the-knee (BTK) lesions. Feiring and colleagues
nrolled 106 patients in a prospective, nonrandomized trial. There were no procedural deaths.
he 3-year cumulative incidence of amputation was 6% and survival was 71%. While repeat
ngiography was not mandated, the estimated binary restenosis was 12%. Treating BTK-CLI
ith drug-eluting stents (DES) appears to safely reduce the need for major amputations.ORONARY ARTERY DISEASE1590Serial Assessment of Coronary Artery Lesion Morphology by VH-IVUSakashi Kubo, Akiko Maehara, Gary S. Mintz, Hiroshi Doi, Kenichi Tsujita, So-Yeon Choi,
samu Katoh, Kenya Nasu, Andreas Koenig, Michael Pieper, Jason H. Rogers, William Wijns, Dirk Böse,
. Pauliina Margolis, Jeffrey W. Moses, Gregg W. Stone, Martin B. Leon
ubo and colleagues used virtual histology intravascular ultrasound (VH-IVUS) to investigate
he natural history of coronary artery lesion morphology by comparing baseline and 12-month
ollow-up studies of nonculprit lesions. During follow-up, 75% of VH-IVUS–thin-capped
broatheromas (VH-TCFAs) “healed”—13 became thick-capped and 2 became fibrotic
laque. Conversely, 12 new VH-TCFAs developed; 6 from areas of pathological intimal
hickening and 6 were thick-capped at baseline. This technique may be useful for assessing
he efficacy of interventions designed to reduce the risk of plaque rupture.Editorial Comment: Efthymios N. Deliargyris, p. 1598ORONARY ARTERY DISEASE1600Presence of Plaque and CIMT Can Improve Risk Stratificationijay Nambi, Lloyd Chambless, Aaron R. Folsom, Max He, Yijuan Hu, Tom Mosley, Kelly Volcik,
ric Boerwinkle, Christie M. Ballantyne
ambi and colleagues evaluated whether carotid intima-media thickness (CIMT) and the
resence or absence of plaque in the carotids improves coronary heart disease (CHD) risk
rediction. Risk prediction models were created using data from the ARIC (Atherosclerosis
isk In Communities) trial. The presence of plaque in the carotid arteries was defined with
of 3 criteria: abnormal wall thickness, abnormal shape, and abnormal wall texture. The
ddition of CIMT and plaque separately or together to traditional risk factors improved the
rea under the curve and the net reclassification index and may improve CHD risk prediction.
ditorial Comment: James H. Stein, Heather M. Johnson, p. 1608(continued on page A-22)
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EIPID-LOWERING THERAPY1611Efficacy and Safety of Mipomersen, an Apo B Synthesis Inhibitoratima Akdim, Erik S. G. Stroes, Eric J. G. Sijbrands, Diane L. Tribble, Mieke D. Trip,
. Wouter Jukema, JoAnn D. Flaim, John Su, Rosie Yu, Brenda F. Baker, Mark K. Wedel,
ohn J. P. Kastelein
kdim and colleagues report the results of a Phase II study to evaluate the effects of mipomersen
n hypercholesterolemic subjects on statin therapy. Mipomersen is an antisense oligonucleotide
esigned to inhibit production of human apolipoprotein (apo) B-100 in the liver. Subjects received
doses over 5 weeks in the first 5 cohorts, and 15 doses of 200 mg over 13 weeks in the sixth
ohort. Apo B and low-density lipoprotein (LDL) cholesterol were reduced by 19% to 54% and
1% to 52%, respectively, in the 5-week cohorts. In the 13-week treatment cohort, LDL
evels were further reduced, but 50% of subjects had elevations 3 times the upper limit of
ormal in liver transanimases. Mipomersen may help patients not reaching target LDL
holesterol levels with statins, but the transanimase elevations will require further study.XERCISE CONDITIONING
1619o Evidence of Cardiac Dysfunction
With Intense, Uninterrupted Endurance Trainingntonio Pelliccia, Norimitsu Kinoshita, Cataldo Pisicchio, Filippo Quattrini, Fernando M. DiPaolo,
oberto Ciardo, Barbara Di Giacinto, Emanuele Guerra, Elvira De Blasiis, Maurizio Casasco,
ranco Culasso, Barry J. Maron
tudies in cyclists have suggested that highly-intensive and uninterrupted athletic conditioning
ould result in left ventricular (LV) dysfunction. Pelliccia and colleagues assessed cardiac
imensions and function in 114 Olympic athletes participating in endurance disciplines, who
rained for consecutive Olympic Games. Global LV systolic function was unchanged during
ollow-up, as were LV volumes and LV mass index. In Olympic athletes, extreme and
ninterrupted endurance training over long periods of time (up to 17 years) was not
ssociated with deterioration in LV function.ditorial Comment: Paul S. Bhella, Benjamin D. Levine, p. 1626PRE-CLINICAL RESEARCH RE-CLINICAL RESEARCH1629The Role of Monocytes in Post-MI Healingeter Panizzi, Filip K. Swirski, Jose-Luiz Figueiredo, Peter Waterman, David E. Sosnovik, Elena Aikawa,
eter Libby, Mikael Pittet, Ralph Weissleder, Matthias Nahrendorf
anizzi and colleagues investigated the role of monocytes after a myocardial infarction using
ice models. The first study showed that atherosclerotic (apoE/) mice had 10 times
ore Ly-6Chi monocytes, which digest damaged tissue, compared to wild type mice in
ardiac samples 5 days after coronary ligation. These results were correlated to higher levels of
roteolysis and phagocytosis and deterioration of ejection fraction. The roles of these
onocytes was further confirmed by artificially inducing Ly-6Chi monocytosis with serial
njections of lipopolysaccharide in wild-type mice. These findings position monocyte subsets
s potential therapeutic targets to augment tissue repair after infarction.ditorial Comment: Larissa Cardilo-Reis, Joseph L. Witztum, Christoph J. Binder, p. 1639
